



# INVESTOR OVERVIEW

[WWW.CVRMED.COM](http://WWW.CVRMED.COM)

## STROKE STATISTICS



### Canada:

Stroke occurs every  
9 minutes

### United States:

Stroke is the third leading  
cause of death and occurs  
every 40 seconds



### Globally:

Leading cause of  
disability globally



50% cause permanent  
impairment



12% are fatal

## About CVR Medical

CVR Medical Corp. is a med-tech organization dedicated to the development and advancement of revolutionary technology at work within the healthcare sector. Specifically, The Carotid Stenotic Scan (CSS), a groundbreaking tool which will be used to assess Carotid Arterial health in a way which is unavailable to the patient, healthcare provider, and the payor within the current system.

## Quick Facts

- Primary Care Office currently lacks tool necessary to assess Stroke risk
- Device is non-invasive and non-emitting, supporting lower risk Class II product classification
- Clinical Trials: In excess of 1,000 Carotids tested
- Device does not require advanced licensing to administer and can fit within the primary care office space



# COMPANY STRUCTURE

**HEAD OFFICE**  
Vancouver, BC

## CAPITAL STRUCTURE (30th Sept 2016)

**TSX-V Trading Symbol:**  
CVM.V

**CUSIP:**  
126632108

**Shares on Issue:**  
41,523,228

**Options:**  
(\$0.21) 6,000,000

**Warrants:**  
(\$0.40) 11,491,183  
(Expire Sept 15, 2018)

## CONTACT

**Address**  
14th Floor, 1111 West Georgia  
Vancouver, British Columbia  
V6E 4M3

**Email**  
info@cvrmed.com

**Investor Relations**  
Brisco Capital Partners Corp.

**Phone**  
(403) 262-9888

## Investment & Industry Highlights

- Total investment to date is excess of \$20 million USD
- Cost of Stroke to the medical industry: \$72 billion USD  
(this number is expected to triple)

## The Market

US MARKET OPPORTUNITY (OFFICES) – CSS			
Primary Care Offices	184,845	<b>\$49,000</b> (Estimated Sales Price of CSS)	\$9,057,405,000
Specialist Offices	40,000		\$1,960,000,000
Hospitals / Clinics	9,770		478,730,000
*Assuming only 1 device sold per office. Most offices will offer multiple sale opportunities		<b>Total US Market Opportunity</b>	<b>\$11,496,135,000</b>

EARLY ADOPTERS YEAR 1 CSS SALES PROJECTIONS	
Sales Reps	440
Offices Visited (Monthly)	48,400
Estimated Rate of Closing	1.1%
Total Device Sales (Monthly)	484
Revenue (Per CSS)	\$49,000
Revenue (Monthly)	\$23,716,000
<b>Total Year 1 Revenue (CSS)</b>	<b>\$284,592,000</b>

## Partners

tekna.

ADCO CIRCUITS

ROGAN Corporation

TDK

Midwest Mold

HITACHI

This presentation may contain forward-looking statements, and forward looking information under applicable securities laws including management's expectations of future production, cash flow and earnings. These statements are based on current expectations that involve a number of risks and uncertainties, which could cause actual results to differ from those anticipated. These risks and uncertainties include, but are not limited to: the risks associated with the medical device industry (e.g. operational risks in development, production; delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of market estimates; the uncertainty of estimates and projections relating to production, costs and expenses, health and safety risks), price and exchange rate fluctuation and uncertainties resulting from potential delays or changes in plans with respect to development projects or capital expenditures. Other than as required by law, CVR does not intend, and undertakes no obligation to update any forward-looking information to reflect, among other things, new information or future events.